Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.

Survival analysis anticipates the expected lifespans of individuals as well as the timing of other events. Learn about its pros and cons.

Explore recursive SNARKs and proof composition in blockchain, boosting scalability, efficiency, and secure zero-knowledge verification ...

Anthropic's Claude Opus 4.6 surfaced 500+ high-severity vulnerabilities that survived decades of expert review. Fifteen days later, they shipped Claude Code Security. Here's what reasoning-based ...

In this tutorial, we build an end-to-end cognitive complexity analysis workflow using complexipy. We start by measuring complexity directly from raw code strings, then scale the same analysis to ...

Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

Plume, a real world asset (RWA)-focused blockchain project, has debuted its Nest yield vaults directly on Solana, giving the network’s users native access to institutional-grade real-world assets for ...

The new managed functions will let enterprises apply LLM reasoning to structured and unstructured data directly in SQL, eliminating prompt tuning and external tools. Google has boosted its BigQuery ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...